生物科技公司药明生物今日盘中股价大涨5.22%,引发市场关注。这与公司日前发布的业务发展预期和利润预测密切相关。
据报道,药明生物管理层在医疗健康行业大会上表示,公司在2024年新签151个项目,并可获得1.4亿美元的里程碑付款,显示业务拓展有序。药明生物的海外业务也在稳步推进,预计2025年爱尔兰生物制药工厂实现盈利。
针对业绩指引,管理层重申2024年公司收入和经调整净利润有望同比增长5-10%,并预计2025年收入增长将进一步加速。同时,公司的营运效率亦有望在2025年提高100至150个基点。有分析认为,这一系列乐观展望增强了市场对药明生物长远发展前景的信心,推动股价出现大涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.